Good virological response to pegylated interferon alfa monotherapy of chronic hepatitis C infection in hemodialysis patient;Buena respuesta a interferón npegilado en monoterapia en paciente con VHC+ en hemodiálisis

Nefrologia

Volumn 27, Issue 1, 2007, Pages 77-80

  Caro Acevedo, Pilar ^a   Nunez A ^a   Delgado, R ^a   Dapena, F ^a   Amann, R ^a  

^a HOSPITAL RUBER INTERNACIONAL   (Spain)

Author keywords

Chronic hepatis C; Hemodialysis; HVC; Pegylated IFN

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; FEMALE; HEPATITIS C; HUMAN; REMISSION; RENAL REPLACEMENT THERAPY;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; RENAL DIALYSIS;

EID: 34447107363     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Strader DB, Wright T, Thomas D y cols.: Diagnosis, manegement and treatment of hepatitis C. Hepatology 39: 1147-1171, 2004.
2. GUÍAS DE TRATAMIENTO DE LA HEPATOPATÍA POR VHC EN HEMODIÁLISIS. SEN 2003.
3. Espinosa M, Rodríguez M, Martín-Malo A y cols.: Interferon therapy hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 55: 220-226, 2001.
4. Campistol JM, Esforzado N, Martínez J y cols.: Efficacy and tolerance of Interferon-alfa 2b in the trreatment of chronic hepatitis C virus infection in haemodialysis patients. Pre and post-renal transplantation assessment. Nephrol Dial Transplant 14 (11): 2704-2709, 1999.
5. Huraib S, Tanimu D, Romeh SA y cols.: Interferon-alfa in chronic hepatitis C virus infection in dialysis patients. Am J Kidney Dis 34: 55-60, 1999.
6. Koenig P, Vogel W, Umlauft F y cols.: Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45: 1507-1509, 1994.
7. Raptopoulou-gigi M, Spia S, Garifallos S y cols.: Interferonalfa 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 10: 1834-1837, 1995.
8. Barril G, Sánchez Tomero JA, García-Buey L y cols.: Response to alfa2b Interferon treatment in one hemodialysis patient with chronic hepatitis C. Nephrol Dial Transplant 9; 1354-1355, 1994.
9. Chan TM, Wu JY, Lau N y cols.: Interferon treatment for hepatitis C infection in patients on hemodialysis. Nephrol Dial Transplant 12; 1414-1419, 1997.
10. Reddy KR, Wright TL, Pockros PJ y cols.: Efficacy and safety of pegylated interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433, 2001.
11. Heathcote EJ, Shiffman ML, Cooksley WG y cols.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343, 1673, 2000.
12. Pockros PJ, Heathcote EJ, Shiffman ML y cols.: Efficacy of pegylated interferon alfa-2a (Pegasys) in randomized trial of patients with chronic hepatitis C, with cirrhosis and without cirrhosis: Correlation of vitologic response with baseline liver histology and genotype. Hepatology 32: 442, 2000.
13. Perillo RP, Thuluvath PJ, Rothstein K y cols: Improved work productivity, safety and quality of life with pegylated interferon alfa-2a (Pegasys) therapy in treatment of chronic hepatitis C. Hepatology 32: 362, 2000.
14. Hassanein TI, Cooksley G, Sulkowsky M y cols.: Treatment with PEG interferon alfa-2a (Pegasys) in combination with ribavirin significantly enhances quality of life comparated with interferon alfa-2a plus ribavirin. Hepatology 34: 243, 2000.
15. Fried MW, Shiffman M, Reddy KR y cols.: Peginterferon alfa-2a plus Ribavirin for chronic hepatitis C virus infection. N Engl J Med 347; 975-982, 2002.
16. Shiffman M, Di Bisceglie AM, Lindsay KL: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who has failed prior treatment. Gastroenterology 126: 1015-1019, 2004.